Bosutinib

Bosutinib
Product Description

Bosutinib is used to treat chronic myeloid leukaemia (CML), a cancer of the white blood cells, in adults with a special chromosome in their cells called the Philadelphia chromosome.Bosutinib is available in three strengths, 100, 400 and 500mg, all three strengths are being developed here in our R&D facility in Iceland. We plan to have the dossier available in Q4 2022 and have secured a DCP slot in December this year.

Read more Show less

Coripharma

  • IS
  • 2020
    On CPHI since
  • 100 - 249
    Employees
Company types
Pharmaceutical company
View company profile
Categories
more categories Show less
Specifications
  • Selling Points
    Quality Service; Sustainability
More specifications Fewer specifications
Sales Markets
Show more Show less

Coripharma

  • IS
  • 2020
    On CPHI since
  • 100 - 249
    Employees
Company types
Pharmaceutical company
View company profile

More Products from Coripharma (4)

  • Coripharma Dossier List

    Product Coripharma Dossier List

    We offer out-licensing of our own developed dossiers, along with a range of services that enable our customers to take products to their respective markets at the date of patent expiry and under their own brand. Currently we have over 20 own developed dossiers on our pipeline and our dossier list is readil...
  • Raltegravir 600mg

    Product Raltegravir 600mg

    Raltegravir is an HIV medicine that is used in combination with other HIV medicines to treat patients who are infected with human immunodeficiency virus (HIV‑1), a virus that causes acquired immune deficiency syndrome (AIDS).Raltegravir 600mg Film-coated tablets has passed its pivotal bioequivalence s...
  • Tolvaptan

    Product Tolvaptan

    Used to treat adults with autosomal dominant polycystic kidney disease.7.5mg, 15mg, 30mg: is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH).
    15+45mg, 30+60mg, 30+90mg: is indicated to slow the progression of cy...
  • Ruxolitinib

    Product Ruxolitinib

    Ruxolitinib is used for the treatment of symptoms in adult patients with primary myelofibrosis which is a rare form of blood cancer. Ruxolitinib comes in four strengths, 5 mg, 10 mg, 15 mg and 20 mg. Pivotal BE study is completed and passing and we expect to have the dossier available in Q1 2024.